The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Nutrition and ExerciseNutrition and Exercise
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Ibalizumab and apricitabine on early access
Feb 3, 2015

Nelson good to see Ibalizumab in early access

and a friend in the US just received their first apricitabine on early access, the ozzie nrti for treatment experienced,

would be good to get the word out about these options together, as well as the upcoming BMS options

Response from Mr. Vergel

Both drugs are available via single patient early access but both companies (Taimed and Avexa) are small and have limited funding, so they are requesting a cost recovery option in which the patient's physician tries to get insurance companies to pay for either investigational drug. This is legal per FDA policy but we have never had a precedent in which an insurance company would pay for drugs not yet approved by the FDA. The out of pocket cost for each drug would be around $1200 per month, an prohibitive cost for most HIV patients.

I hope these two companies get their needed funding to proceed with phase 3 since both drugs have value in treating patients with HIV multidrug resistance.


strengthening the spine

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint